A drug that could control the number of relapses which a multiple sclerosis sufferer has been rolled out with its first patient trial, it has been announced.
Biogen Idec, which pioneered the PEGylated interferon beta-1a treatment, is to use a randomised double-blind placebo-controlled trial to evaluate how efficient the drug can be in fighting against the condition.
It is hoped the new treatment will reduce the number of injections a sufferer has as part of their treatment.
Michael Panzara, the vice-president and chief medical officer of neurology at Biogen Idec, explained that his company was aiming to protect the long-term wellbeing of individuals, adding that by bringing PEGylation forward as a multiple sclerosis treatment, it could be applauded by the medical community.
He added: "Biogen Idec is committed to improving the lives of MS patients by delivering first-in-class treatments, unparalleled patient support and cutting-edge research as we continue to work towards a cure and redefine success in the treatment of this debilitating disease."
Earlier this month, more good news was offered to elderly people, with the government announcing that it would be moving the basic state pension age to make it equal regarding gender, as well as helping the payments to be increased each year in line with average earnings.
Please click here for advice to help you find the right type of care.